Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Brian joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva's Executive Vice President and Interim Global Chief Legal Officer. During his tenure, he also led Teva's global litigation strategy and served as General Counsel for its U.S. Generics business.
Prior to joining Teva, Brian practiced law at Dechert LLP. Brian brings extensive experience navigating the complex legal and regulatory landscape in the global pharmaceutical industry. He holds a Juris Doctor (J.D.) from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania.
Lupin has launched Formoflo-G® MDI, the world's first fixed dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI). The launch marks a significant advancement in respiratory care, expanding treatment options for patients living with COPD.
Lupin Formoflo-G® is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India, a condition that remains a leading cause of death and disability.
Consequently, effective 01 October 2026, MPPI has become a wholly owned subsidiary of Nanomi and step-down wholly owned subsidiary of the Company.
Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.
Lupin's Apixaban Oral Suspension 1.25 mg/mL is an oral liquid formulation of apixaban, the active ingredient in Eliquis® (apixaban) of Bristol Myers Squibb, and provides an alternative administration option for adult patients requiring anticoagulation therapy Including those who may have difficulty swallowing tablets.
Upon final approval, the product will be manufactured at Lupin's Somerset, New Jersey facility, leveraging the company's U.S.-based manufacturing expertise to support high-quality standards, and supply reliability.
Apixaban is an oral liquid formulation of apixaban, the active ingredient in Eliquis (apixaban) of Bristol Myers Squibb. The drug provides an alternative administration option for adult patients requiring anticoagulation therapy, including those who may have difficulty swallowing tablets.
Apixaban is an oral anticoagulant used to prevent and treat blood clots and reduce the risk of stroke in people with nonvalvular atrial fibrillation.
Upon final approval, the product will be manufactured at Lupin's Somerset, New Jersey facility.
Vinita Gupta, CEO, Lupin, said: 'This tentative approval reflects our continued focus on developing differentiated medicines that address meaningful patient needs.
Apixaban oral suspension expands the ways in which this important therapy could be administered, while reinforcing our commitment to building a differentiated portfolio.'
Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapeutic segments.
The company’s consolidated profit after tax stood at Rs 1,415 crore in Q1 FY27, up 16.08% from Rs 1,219.03 crore in Q1 FY26. Net sales rose 33.32% to Rs 8,217.23 crore in Q1 FY27 as compared with Q1 FY26.
Lupin Ltd is down for a fifth straight session today. The stock is quoting at Rs 2104.3, down 0.02% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.4% on the day, quoting at 23541.1. The Sensex is at 75140.89, down 0.58%.Lupin Ltd has lost around 8.51% in last one month.Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has increased around 0.92% in last one month and is currently quoting at 26880.8, down 0.59% on the day. The volume in the stock stood at 3.18 lakh shares today, compared to the daily average of 9.12 lakh shares in last one month.
The benchmark September futures contract for the stock is quoting at Rs 2110.5, up 0.24% on the day. Lupin Ltd jumped 6.29% in last one year as compared to a 5.73% slide in NIFTY and a 20.8% spurt in the Nifty Pharma index.
The PE of the stock is 14.58 based on TTM earnings ending June 26.
The U.S. FDA has approved Lupin's Modafinil Tablets USP, 100 mg and 200 mg as bioequivalent to the reference listed drug (RLD), Provigil® Tablets of Nuvo Pharmaceuticals (Ireland) DAC, and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) or shift work disorder (SWD).
Modafinil Tablets (RLD Provigil®) had estimated annual sales of USD 70.7 million in the U.S. (IQVIA MAT Jul 2026).
In view of the above, the issued and paid-up share capital of the Company has increased to Rs 91,45,31,722 consisting of 45,72,65,861 equity shares of Rs 2/- each.